Prescription medicine
Acoramidis Brand names: Attruby
Acoramidis (Attruby) is a prescription medicine with an FDA approval on record since 2024. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the acoramidis FDA label on DailyMed (effective June 29, 2026, BridgeBio Pharma, Inc.); the NDA 216540 record on Drugs@FDA; every acoramidis label on DailyMed.
Highlights of the record
FDA label of June 29, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Forms and strengths
- 356 mg
Film-coated tablet.
On the market
- Earliest approval on file
- November 22, 2024 Attruby, Bridgebio Pharma; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- August 16, 2039 Attruby tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 306 through July 30, 2026
What is acoramidis used for?
From the label: indications and usageATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ATTRUBY is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
FDA pharmacologic class: Transthyretin Stabilizer.
Source: FDA drug label (Attruby), BridgeBio Pharma, Inc., effective June 29, 2026 (SPL set 913552ef-875d-4cb7-bf05-a7d20a394c38), via openFDA; the full label on DailyMed
Is there a generic for acoramidis (Attruby)?
No generic acoramidis is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 13 patents for Attruby tablets: the compound patent runs to February 16, 2038, and the last listed entry to August 16, 2039. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2024 earliest approval on file
- 2039 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for acoramidis?
The FDA Adverse Event Reporting System holds 306 reports that list acoramidis among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 8 are coded as a death and 35 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Acoramidis side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other